http://orcid.org/0000-0002-3366-2110
Figures
Abstract
Lafora disease (LD) is an autosomal recessive late onset, progressive myoclonic epilepsy with a high prevalence in the miniature Wirehaired Dachshund. The disease is due to a mutation in the Epm2b gene which results in intracellular accumulation of abnormal glycogen (Lafora bodies). Recent breed-wide testing suggests that the carrier plus affected rate may be as high as 20%. A characteristic feature of the disease is spontaneous and reflex myoclonus; however clinical signs and disease progression are not well described. A survey was submitted to owners of MWHD which were homozygous for Epm2b mutation (breed club testing program) or had late onset reflex myoclonus and clinical diagnosis of LD. There were 27 dogs (11 male; 16 female) for analysis after young mutation-positive dogs that had yet to develop disease were excluded. Average age of onset of clinical signs was 6.94 years (3.5–12). The most common initial presenting sign was reflex and spontaneous myoclonus (77.8%). Other presenting signs included hypnic myoclonus (51.9%) and generalized seizures (40.7%). Less common presenting signs include focal seizures, “jaw smacking”, “fly catching”, “panic attacks”, impaired vision, aggression and urinary incontinence. All these clinical signs may appear, and then increase in frequency and intensity over time. The myoclonus in particular becomes more severe and more refractory to treatment. Signs that developed later in the disease include dementia (51.9%), blindness (48.1%), aggression to people (25.9%) and dogs (33.3%), deafness (29.6%) and fecal (29.6%) and urinary (37.0%) incontinence as a result of loss of house training (disinhibited type behavior). Further prospective study is needed to further characterize the canine disease and to allow more specific therapeutic strategies and to tailor therapy as the disease progresses.
Citation: Swain L, Key G, Tauro A, Ahonen S, Wang P, Ackerley C, et al. (2017) Lafora disease in miniature Wirehaired Dachshunds. PLoS ONE 12(8): e0182024. https://doi.org/10.1371/journal.pone.0182024
Editor: Francesc Palau, Sant Joan de Déu Children's Hospital, SPAIN
Received: December 15, 2016; Accepted: July 11, 2017; Published: August 2, 2017
Copyright: © 2017 Swain et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Data Availability: All relevant data are within the paper and its Supporting Information files.
Funding: The Kennel Club Charitable Trust registered charity (No. 327802) partially subsidized the cost of genetic testing of many of the dogs in this study. The Dachshund Breed Council coordinated fundraising to contribute towards the cost of genetic testing. The genetic work was part funded by the Ontario Brain Institute and the National Institute of Neurological Disorders and Stroke of the National Institutes of Health (NIH) under award number P01 NS097197. Fitzpatrick Referrals Ltd, provided support in the form of salaries and materials for authors LS, AT and CR. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript with the exception of the Dachshund Breed Council which has a Health and Welfare subcommittee which instigated the data collection but did not play a role in analysis.
Competing interests: AT and CR are and LS was employed by Fitzpatrick Referrals Ltd, Surrey, GU7 2QQ. CR is also employed by the University of Surrey. SA, PW, CA and BM are employed by the Hospital for Sick Children, University of Toronto. The University of Surrey, The University of Toronto and Fitzpatrick Referrals Ltd did not play a role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript and only provided financial support in the form of authors' salaries and/or research materials. GK is a member of the Lafora disease Subcommittee which is part of the Dachshund Breed Council affiliated with the UK Kennel Club. The Dachshund Breed Council represents the interests of sixteen UK Dachshund Breed Clubs and appoints Health and Welfare Sub-committees to develop policies and coordinate plans for Dachshund breed health improvement. The Lafora disease subcommittee instigated data collection but did not play a role in analysis, decision to publish, preparation of the manuscript or provide financial support other than coordinate fundraising to partially subsidize the cost of genetic testing. None of the authors have personal or financial relationships with other people or organizations that might inappropriately influence or bias the content of the paper. There are no patents, products in development, or marketed products to declare. This does not alter the authors' adherence to PLOS ONE policies on sharing data and materials.
Introduction
Lafora disease (LD) is an autosomal recessive myoclonic epilepsy caused by mutations in the EPM2A gene, encoding the glycogen phosphatase laforin, or the EPM2B gene coding the ubiquitin E3 ligase malin [1–3]. In humans, LD is arguably the severest adolescence-onset epilepsy [4]. Its early signs are myoclonus and generalized tonic-clonic seizures, along with transient blindness, visual hallucinations (often with frightening content) or photoconvulsions. As the disease progresses the severity, frequency and refractoriness of the seizures increase. Ataxia and emotional disturbances develop, followed by spasticity and dementia. A vegetative state in constant myoclonus precedes death, which occurs in status epilepticus approximately 10 years after onset [3, 5]. The mutations in human LD are numerous, spread in all regions of either gene, all leading to loss of function [2, 6].
In dogs, LD is also inherited as an autosomal recessive condition and is one of the most common recognized structural-metabolic epilepsies [7]. It is most frequent in Miniature Wirehaired Dachshunds (MWHD) [1, 8, 9], Bassett Hounds [1, 10] and Beagles [11, 12], and single cases have been reported in the Miniature and Standard Poodle [13], Pointer [14], and a Corgi [15]. LD has also been reported in other species including a Fennec fox [16], cows [17] and possibly a parakeet [18]. Clinical signs are similar to those of the human disease, including spontaneous and reflex myoclonus, hypnic jerks and generalized tonic clonic seizures [1]. Complete blood count, serum biochemistry, urinalysis and cerebrospinal fluid are normal [8, 9]. Electroencephalographic (EEG) measurements reveal bilateral synchronous polyspike-wave paroxysms and erratic myoclonus without EEG correlation [11]. Magnetic resonance imaging (MRI) may reveal generalized cortical atrophy with ventriculomegaly (Fig 1) [1, 9]. Needle electromyography (EMG) has been reported to show abnormal spontaneous activity of the muscles with positive sharp waves and fibrillation potential [8].
(a) Mid-sagittal T2W image of the brain demonstrating atrophy of the intra-thalamic adhesion (*). (b) Transverse T2W at the level of temporal lobes demonstrating cortical atrophy with widening of the subarachnoid space (green arrow) and enlargement of the lateral ventricle (orange arrow). (c) Transverse T2W at level of occipital lobes demonstrating cortical atrophy with widening of the subarachnoid space (green arrow) and enlargement of the lateral ventricle (orange arrow).
To date, a single mutation has been found in canine LD, in all three of three breeds (MWHD, Bassett Hounds and Beagles) in which mutation testing has been performed [1, 12]. This mutation consists of a massive expansion of a dodecamer repeat sequence present exclusively in the canine (and generally canid) Epm2b gene, leading to near-absent expression and loss of function of the gene [1, 12]. Genetic testing is not routinely available because the massive dodecamer repeat expansion mutation makes PCR-based sequencing options unreliable for detecting the carrier state and consequently only a southern blot based test is offered by the University of Toronto and is an official DNA screening test recommended by the UK Kennel Club (Fig 2)
The DraIII-EcoR fragment of EPM2B gene in wild-type animal is 980 base pairs (bp), while the same fragment of EPM2B mutation allele in affected or Carrier animals is around 1200 bp.
The underlying pathology in LD is transformation of spherical and soluble glycogen to a more linear and insoluble glucan called polyglucosan. Gradual precipitation, aggregation, and accumulation of polyglucosans results in massive neurotoxic inclusions (Lafora bodies; LB), which drive the neurodegenerative epilepsy [3] (Fig 3).
A. PAS diastase (PASD) treated section of frontal cortex from the brain of a MWHD with Lafora disease collected at autopsy. Note the numerous PASD positive Lafora Bodies (LB) (arrows) located in the perikaryon of many of the neurons. Much smaller LBs are located throughout (small arrows). Bar equals 50μm. B. Electron micrograph of a LB in the terminal cytoplasm of a dendrite. A synaptic density is seen (arrow). Bar equals 500nm.
Precisely how the laforin-malin partner enzymes regulate glycogen structure remains unclear [19, 20]. Notwithstanding, a shortcut to therapy was recently suggested. Glycogen synthase is the only enzyme that catalyzes formation of α1–4 interglucosidic linkages that generate glycogen (or polyglucosan) strands. Mere 50% reduction of glycogen synthase activity in LD mouse models through transgenic approaches was shown to eliminate LB and the neurological phenotype of the disease [5, 21–23]. As such, work is actively underway to identify glycogen synthase inhibitors towards a potential therapy for LD, human and canine. Clinical trials require detailed description of the clinical disease and its natural progression. This paper fills an important part of this void for canine LD.
Ethics statement
This retrospective study was based on the analysis of responses to a confidential online survey which did not collect personal data and no aspect comes under the auspices of Animals (Scientific Procedures) Act 1986. Informed written consent to use data was obtained from survey participants. Ethics committee approval for this project was not sought because the decision to create and run the survey was made by the Lafora disease subcommittee (part of the Dachshund Breed Council) and ethics approval cannot be made retrospectively.
Materials and methods
The Dachshund Breed Council is affiliated with the UK Kennel Club and represents the interests of sixteen UK Dachshund Breed Clubs and appoints Health and Welfare Sub-committees to develop policies and coordinate plans for Dachshund breed health improvement. One of these is the LD Subcommittee which constructed an online survey in 2012 with the aim of assessing the clinical signs and impact of LD [24, 25]. Common signs of disease were identified: myoclonic jerks (spontaneous and reflex, most commonly induced by light, sound or sudden movement in the visual field), hypnic myoclonus (twitch as falling asleep), seizures (both focal and tonic-clonic), ataxia, poor vision/blindness, deafness, dementia (defined as a behavior change suggesting disorientation and memory loss with or without altered sleep wake cycle and anxiety), aggression (toward people and other dogs), incontinence due to loss of house training i.e. disinhibited behavior (both fecal and urinary), jaw smacking and fly catching however the survey did not include data on how this disease progressed. Consequently, in 2013 the online survey was refined to include information about age of onset, progression of clinical signs, comorbidities, impact of disease and, if applicable, age of death (S1 Text) [26]. The confidential online survey ran between January 2013 and January 2014. Participants were invited if they had previously contacted the MWHD Lafora subcommittee about pets with clinical signs of LD and/or if they had participated in bi-annual bulk genetic testing for LD through the Dachshund Breed Council [25]. Participants gave their written consent for the clinical data to be used for research purposes and the raw data from the survey (S1 Table) was subsequently passed to this group with a request for analysis to provide information on disease progression and further knowledge of the disease.
Inclusion criteria for the analysis was a UK bred MWHD that had either positive genetic testing for LD or had showed pathognomonic signs of LD including reflex myoclonic jerks, had medical history available for review and died before genetic testing was available. Survey responses were excluded if the dogs were not UK bred MWHD or were mutation positive and not yet showing clinical signs. All dogs that tested negative for LD were also excluded.
Results
Signalment
Forty-one online responses were received. Fourteen dogs were immediately excluded from the study as they were not showing clinical signs at the time of the study; four of these dogs had tested positive for the LD disease mutation but did not yet show clinical signs (all these dogs were younger than the age of onset of canine LD). Of the remaining 27 dogs, 16 were confirmed homozygous for the LD mutation via genetic testing. The remaining 11 dogs were not tested as they died prior to the genetic test being available. All, however, had the classical clinical disease including spontaneous and reflex myoclonic jerks. The signalment results are illustrated in Table 1. 62.5% of the cohort was female. The mean age of onset of clinical signs was 6.94 years which correlated with the median age of onset of 7 years. The range of the onset of clinical signs was wide at 3.5 to 12 years.
Clinical signs at presentation
Table 2 illustrates the distribution of fourteen common clinical signs at presentation in LD for both mutation-positive and untested cases. The most common sign for both were reflex and spontaneous myoclonus, hypnic myoclonus, generalized seizures, and jaw smacking. The remaining clinical signs at presentation were fly catching and panic attacks, focal seizures, aggression toward people, urinary incontinence as a result of loss of house training, poor vision or blindness, fecal incontinence, or dementia.
Early clinical signs (years 1–3 following onset)
In the gene test-positive group the most frequent new clinical sign that developed over the first 1–3 years following presentation was poor vision /blindness which was reported in over one third of the dogs. Other common signs were generalized tonic clonic seizures, hypnic myoclonus, panic attacks and dementia. Less frequent signs were jaw smacking, fly catching, focal seizures, aggression toward other dogs, fecal incontinence as a result of loss of house training, and deafness. The untested group had slightly different development of clinical signs, the most frequent being dementia, which was reported in two thirds of the cases, followed by focal seizures. Less frequent clinical signs are illustrated in Table 3
Late clinical signs (>3 years)
Late onset clinical signs (those developing 3 years or more after initial presentation) in the mutation-positive group were dementia followed by panic attacks, urinary incontinence, and deafness (Table 4). In the untested group the most common developing late clinical signs were those of aggression towards other dogs and urinary and fecal incontinence as a result of loss of house training (disinhibited).
Discussion
Our study showed that LD in the MWHD is a progressive myoclonic epilepsy similar to the disease process in humans. The disease is late onset with an average age of approximately 7 years at presentation. The cardinal features of the disease are: spontaneous myoclonus, reflex myoclonus (myoclonus in response to light, sounds and / or movement in visual field), hypnic jerks (jerking as falling asleep), generalized seizures, focal seizures, anxiety, impaired vision, and later cognitive decline to dementia, ataxia, deafness, and fecal and urinary incontinence as a result of loss of house training (disinhibited behavior). All these clinical signs appear, and then increase over time, in all dogs (S1 Movie). Myoclonus, in particular, becomes progressively more severe although anecdotally there is an initial response to levetiracetum. Owners described the (presumed) panic attacks as particularly distressing and from the description [24] we hypothesize that the dogs may be experiencing frightening visual hallucinations as the dog’s behavior suggested fear and an escape response. Owners of affected dogs stated that they were unable to walk the dog off the leash because if it occurred then the affected dog could run off uncharacteristically. As the disease progresses clinical signs become more intense and often dogs may be euthanized due to their severity. Unlike in humans, LD affected MWHD do not enter a vegetative state in constant myoclonus. This is likely a reflection that they are euthanatized before this stage but also because of their longevity. Affected humans develop the disease in late childhood to early adolescence and die at approximately 25 years of age. It is possible that the dogs do not develop more severe signs because they would die of natural causes first [1].
A genetic database of MWHD bred in the United Kingdom aimed at identifying affected and carrier animals was established by the Dachshund Breed Council [25]. The genetic test offered by the University of Toronto separates the normal, carriers and genetically affected dogs and is now an official DNA screening test recommended by the UK Kennel Club and a requirement for any MWHD breeder who wishes to be accredited in the “Assured Breeder Scheme” [27]. The genetic test is Southern blotting based [12], because PCR-based sequencing options through the massive dodecamer repeat expansion mutation have so far proven inadequately reliable. As such a larger amount of DNA is required than can be obtained from cheek swabs, and generally a blood sample is used. For this reason, the test is still not available through a commercial laboratory. The Southern blot based approach (Fig 2) is presently the only approved test but is expensive for the dog owner and is performed intermittently on batched samples which limits the number of dogs tested. In particular, clinically affected dogs presented to veterinary surgeons are less likely to be tested. Based on data published by the UK Kennel Club the frequency of carriers (34%) and genetically affected dogs (6%) is high [27] although this figure does not include hereditary clear dogs and the estimated carrier and affected rate may be closer to 20% (Ian Seath, personal communication). The genetic test is the definitive test in confirming the disease and the percentage for mutation positive dogs has decreased since breed wide testing has been implemented.
The precise roles of the Epm2a and Epm2b genes remain unknown. What is clear is that the former encodes a phosphatase (laforin) that regulates a small but important amount of phosphate covalently bound to glycogen. This phosphate appears to be critical to ensuring the sphericity of glycogen, which is essential to its solubility. Epm2b, the gene commonly mutated in dogs, encodes an ubiquitin E3 ligase (malin). Which proteins are the precise target(s) of malin remains unknown, but absence of malin’s function, like absence of laforin, leads to poorly branched and insoluble glycogen (polyglucosans), which accumulate in neuronal somatodendritic compartments into Lafora bodies (polyglucosan bodies), over time driving the neurodegeneration and progressive myoclonic epilepsy[28] (Fig 3).
Neuronal somatodendritic polyglucosan bodies in young animals or humans are essentially pathognomonic of LD. In human or canine LD, polyglcuosan bodies are also seen in various tissues outside the brain, such as muscle, heart and liver, but in these organs, they appear to be clinically neutral, usually the patient succumbing to the neurological disease without ever having developed clinical signs of hepatic, cardiac or skeletal muscle disease. Polyglucosan bodies can also be associated with other neurological syndromes often referred to in humans as polyglucosan body disease [29]. In these cases, the polyglucosan bodies are present not in the somatodendritic compartments of neurons, but in their axons or axon hillocks, leading not to an epileptic condition but to an axonopathy resembling amyotrophic lateral sclerosis. Similar syndromes occur in other species including dogs [30] cats [31], and the grey-head flying fox [32]. Non-pathogenic polyglucosan bodies occur as an aging-related change in many species including cats, dogs and man. These are usually present not in neurons but in glia, and in the human literature are termed corpora amylacea. They are an important consideration in canine LD, because in this species the disease is late in onset and brain necropsies could be misconstrued as representing LD in aged dogs [33–39].
Current therapy for LD is aimed at limiting clinical signs of the disease. However, all treatment is anecdotal as no research has been performed to assess the efficacy of individual therapies. Animals suffering from generalized seizures have received licensed anti-epileptic drugs such as phenobarbital at standard doses and unlicensed second or third generation anti-epilepsy drugs such as leviteracetam or zonisamide [9, 40]. Anecdotally, leviteracetam was found to be particularly effective in reducing myoclonus in early disease. In some cases where dogs suffer greatly from photosensitive myoclonus the use of canine specific sun goggles have been used to limit clinical signs. In human patients suffering from LD hallucinations occur regularly, causing anxiety. Although the presence of hallucinations in the canine disease can neither be confirmed nor denied, the use of anxiolyitcs, such as alprazolam, are potentially beneficial in dogs with LD.
Transgenically reducing brain glycogen synthesis by as little as 50% prevents the disease in LD mouse models and is an exciting potential therapeutic avenue [5, 21–23]. This is not possible to achieve merely through dietary restriction, e.g. by using low carbohydrate diets such as the ketogenic diet. Mice (our unpublished observation) and humans [41] in whom this has been tried maintain physiological blood glucose levels and generate just as profuse LB as with normal diet. Despite early promising results [42] longer term observations suggest that feeding a low CRcarbohydrate and/or high antioxidant diet does not delay onset of disease in LD dogs. Achieving reduced brain glycogen synthesis as a therapy for LD will therefore require approaches that directly downregulate glycogen synthesizing enzymes. In work recently published in abstract form, antisense oligonucleotides targeting glycogen synthase eliminated Lafora bodies in LD mouse models, establishing proof of principle for this strategy [43].
As demonstrated by our study, LD is a significant inherited condition in MWHD, and as such knowledge of the disease is pertinent in early detection and diagnosis. For any MWHD suffering with progressive myoclonus or seizure activity treatment with anti-epileptics should be initiated promptly. With the development of the genetic database it should become easier to identify the risk to each individual animal and eventually eliminate LD from the UK MWHD population. While providing a solid baseline for the progression of LD in MWHD this study suffers the weakness of being retrospective and owner based. To more comprehensively and definitively determine the natural progression and treatment of canine LD a prospective study looking at multiple animals with genetically confirmed disease should be completed. Work is very much underway to identify small molecule or other glycogen synthesis inhibitors to achieve 50% reduction in brain glycogen synthesis. A detailed canine natural progression study will allow organization of clinical trials also in dogs. It must be emphasized that dogs with LD, even in the MWHD breed alone, outnumber all known cases of human LD. All affected dogs to date, from all breeds, have the same expansion mutation in the Epm2b dodecamer repeat unique to the canid orthologue of the gene. LD, in this sense, can be regarded as a canine genome particular disease, and is likely to continue to be seen in different purebred breeds with each recurrence of the expansion mutation.
Supporting information
S1 Text. Survey for owners of LD affected dogs.
To improve survey accuracy technical terms were explained within the survey for example generalized seizures were explained as “also known as grand mal or tonic clonic and characterized by initial stiffening of the limbs followed by jerking of the limbs and face”. The survey participant was asked to enter the dog’s age that they first noticed the clinical signs or “never” if this sign was not noticed. There were more specific questions about urinary incontinence to enable assessment as to whether incontinence occurred as a result of loss of house training (i.e. disinhibition and a specific sign of senility) or was more likely due to other causes. There was also open questions to allow participants to enter other clinical signs and other comments. Participants were also asked their opinion on the impact of LD on daily living. Finally there was a question about possible comorbidities including previous diagnosis of intervertebral disease. This is the most common neurological disease in this breed which could be alternative cause of the clinical sign of ataxia.
https://doi.org/10.1371/journal.pone.0182024.s001
(PDF)
S1 Table. Raw data received from LD survey in microsoft excel.
https://doi.org/10.1371/journal.pone.0182024.s002
(XLSX)
S1 Movie. Video of LD affected dogs.
Daisy a 13 year old female spayed MWHD together with her 10 year male neutered son Bertie. Both are mutation positive for LD. As an older dog Daisy is more severely affected and is nearly blind and has a high stepping hypermetric gait particularly of the pelvic limbs with a pelvic limb tremor. Both dogs have spontaneous and reflex myoclonic jerks with an intention tremor.
https://doi.org/10.1371/journal.pone.0182024.s003
(MP4)
Acknowledgments
The authors are grateful to the Dachshund Breed Council, the Wire Haired Dachshund club and Lafora Subcommittee for enabling this project. In particular we would like to thank Ian Seath, Nora Price, Susan Holt and Roger Sainsbury for their considerable support.
References
- 1. Lohi H, Young EJ, Fitzmaurice SN, Rusbridge C, Chan EM, Vervoort M, et al. Expanded repeat in canine epilepsy. Science. 2005;307(5706):81-. pmid:15637270
- 2. Ianzano L, Zhang J, Chan EM, Zhao XC, Lohi H, Scherer SW, et al. Lafora progressive Myoclonus Epilepsy mutation database-EPM2A and NHLRC1 (EPM2B) genes. Human mutation. 2005;26(4):397. pmid:16134145.
- 3. Minassian BA. Lafora's disease: towards a clinical, pathologic, and molecular synthesis. Pediatric neurology. 2001;25(1):21–9. pmid:11483392.
- 4. Kalviainen R. Progressive Myoclonus Epilepsies. Seminars in neurology. 2015;35(3):293–9. pmid:26060909.
- 5. Turnbull J, DePaoli-Roach AA, Zhao X, Cortez MA, Pencea N, Tiberia E, et al. PTG depletion removes Lafora bodies and rescues the fatal epilepsy of Lafora disease. PLoS genetics. 2011;7(4):e1002037. pmid:21552327.
- 6. Singh S, Ganesh S. Phenotype variations in Lafora progressive myoclonus epilepsy: possible involvement of genetic modifiers? Journal of human genetics. 2012;57(5):283–5. pmid:22456482.
- 7. Hulsmeyer VI, Fischer A, Mandigers PJ, DeRisio L, Berendt M, Rusbridge C, et al. International Veterinary Epilepsy Task Force's current understanding of idiopathic epilepsy of genetic or suspected genetic origin in purebred dogs. BMC veterinary research. 2015;11:175. pmid:26316206.
- 8. Schoeman T, Williams J, van Wilpe E. Polyglucosan storage disease in a dog resembling Lafora's disease. Journal of veterinary internal medicine / American College of Veterinary Internal Medicine. 2002;16(2):201–7. pmid:11899039.
- 9. Webb AA, McMillan C, Cullen CL, Boston SE, Turnbull J, Minassian BA. Lafora disease as a cause of visually exacerbated myoclonic attacks in a dog. The Canadian veterinary journal La revue veterinaire canadienne. 2009;50(9):963–7. pmid:19949558.
- 10. Kaiser E, Krauser K, Schwartz-Porsche D. [Lafora disease (progressive myoclonic epilepsy) in the Bassett hound—possibility of early diagnosis using muscle biopsy?]. Tierarztliche Praxis. 1991;19(3):290–5. pmid:1653470.
- 11. Gredal H, Berendt M, Leifsson PS. Progressive myoclonus epilepsy in a beagle. The Journal of small animal practice. 2003;44(11):511–4. Epub 2003/11/26. pmid:14635965.
- 12. Hajek I, Kettner F, Simerdova V, Rusbridge C, Wang P, Minassian BA, et al. NHLRC1 repeat expansion in two beagles with Lafora disease. The Journal of small animal practice. 2016;57(11):650–2. pmid:27747878.
- 13. Holland JM, Davis WC, Prieur DJ, Collins GH. Lafora's disease in the dog. A comparative study. The American journal of pathology. 1970;58(3):509–30. pmid:5436097.
- 14.
Whitenack D, editor Neuronal glycoproteinosis (Lafora's disease) in the dog. American Association of Veterinary Laboratory Diagnosticians; 1978; Madison, WI.
- 15. Davis KE, Finnie JW, Hooper PT. Lafora's disease in a dog. Australian veterinary journal. 1990;67(5):192–3. pmid:2165776.
- 16. Honnold SP, Schulman FY, Bauman K, Nelson K. Lafora's-like disease in a fennec fox (Vulpes zerda). J Zoo Wildl Med. 2010;41(3):530–4. pmid:20945656.
- 17. Simmons MM. Lafora disease in the cow? Journal of comparative pathology. 1994;110(4):389–401. pmid:8056873.
- 18. Loupal G. [A storage disease in a parakeet (Nymphicus hollandicus) morphologically similar to the systemic myoclonic disease (Lafora disease) in man and dog]. Zentralblatt fur Veterinarmedizin Reihe A. 1985;32(7):502–11. pmid:2998123.
- 19. Gayarre J, Duran-Trio L, Criado Garcia O, Aguado C, Juana-Lopez L, Crespo I, et al. The phosphatase activity of laforin is dispensable to rescue Epm2a-/- mice from Lafora disease. Brain: a journal of neurology. 2014;137(Pt 3):806–18. pmid:24430976.
- 20. Nitschke F, Wang P, Schmieder P, Girard JM, Awrey DE, Wang T, et al. Hyperphosphorylation of glucosyl C6 carbons and altered structure of glycogen in the neurodegenerative epilepsy Lafora disease. Cell Metab. 2013;17(5):756–67. pmid:23663739.
- 21. Duran J, Gruart A, Garcia-Rocha M, Delgado-Garcia JM, Guinovart JJ. Glycogen accumulation underlies neurodegeneration and autophagy impairment in Lafora disease. Human molecular genetics. 2014;23(12):3147–56. pmid:24452334.
- 22. Pederson BA, Turnbull J, Epp JR, Weaver SA, Zhao X, Pencea N, et al. Inhibiting glycogen synthesis prevents Lafora disease in a mouse model. Annals of neurology. 2013;74(2):297–300. pmid:23913475.
- 23. Turnbull J, Epp JR, Goldsmith D, Zhao X, Pencea N, Wang P, et al. PTG protein depletion rescues malin-deficient Lafora disease in mouse. Annals of neurology. 2014;75(3):442–6. pmid:24419970.
- 24.
Key G. Survey Results Autumn 2012 2012 [cited 2016 April 16th]. http://laforadogs.org/surveys/interim-survey-results-autumn-2012.
- 25.
Seath I, Holt S. Lafora Disease: Dachshund Breed Council 2014 [cited 2016 April 16th]. https://sites.google.com/site/ukdachshundhealthreport/dachshund-health-resources/lafora-disease.
- 26.
Key G. Progression Survey 2013 [cited 2016 16th April]. http://laforadogs.org/surveys/survey.
- 27.
The_Kennel_Club. Dachshund (Miniature Wire Haired) DNA screening 2016 [cited 2016 April 16th]. http://www.thekennelclub.org.uk/health/breeding-for-health/dna-screening-schemes-and-results/dna-screening-for-breeds-c-g/dachshund-(miniature-wire-haired)-dna-screening/.
- 28. Turnbull J, Tiberia E, Striano P, Genton P, Carpenter S, Ackerley CA, et al. Lafora disease. Epileptic disorders: international epilepsy journal with videotape. 2016;18(S2):38–62. pmid:27702709.
- 29. Mochel F, Schiffmann R, Steenweg ME, Akman HO, Wallace M, Sedel F, et al. Adult polyglucosan body disease: Natural History and Key Magnetic Resonance Imaging Findings. Annals of neurology. 2012;72(3):433–41. pmid:23034915.
- 30. Marquez M, Perez L, Serafin A, Teijeira S, Navarro C, Pumarola M. Characterisation of Lafora-like bodies and other polyglucosan bodies in two aged dogs with neurological disease. Vet J. 2010;183(2):222–5. pmid:19010069.
- 31. Hall DG, Steffens WL, Lassiter L. Lafora bodies associated with neurologic signs in a cat. Veterinary pathology. 1998;35(3):218–20. pmid:9598585.
- 32. Gabor LJ, Srivastava M. Polyglucosan inclusions (Lafora bodies) in a gray-headed flying fox (Pteropus poliocephalus). Journal of veterinary diagnostic investigation: official publication of the American Association of Veterinary Laboratory Diagnosticians, Inc. 2010;22(2):303–4. pmid:20224098.
- 33. Antal M. [Lafora bodies in the retina of various animals]. J Fr Ophtalmol. 1982;5(10):615–20. pmid:6296216.
- 34. Duran J, Guinovart JJ. Brain glycogen in health and disease. Molecular aspects of medicine. 2015;46:70–7. pmid:26344371.
- 35. Kamiya S, Suzuki Y, Sugimura M. Polyglucosan bodies in the digestive tract of the aged dog. Acta neuropathologica. 1983;60(3–4):297–300. pmid:6310929.
- 36. Suzuki Y, Akiyama K, Suu S. Lafora-like inclusion bodies in the CNS of aged dogs. Acta neuropathologica. 1978;44(3):217–22. pmid:216221.
- 37. Suzuki Y, Ohta K, Kamiya S, Suu S. Topographic distribution pattern of Lafora-like bodies in the spinal cord of some animals. Acta neuropathologica. 1980;49(2):159–61. pmid:6243842.
- 38. Suzuki Y, Ohta K, Suu S. Correlative studies of axonal spheroids and Lafora-like bodies in aged dogs. Acta neuropathologica. 1979;48(1):77–81. pmid:116474.
- 39. Yamanami S, Ishihara T, Takahashi M, Uchino F. Comparative study of intraneuronal polyglucosan bodies in brains from patients with Lafora disease and aged dogs. Acta Pathol Jpn. 1992;42(11):787–92. pmid:1335204.
- 40. Kyllerman M, Ben-Menachem E. Zonisamide for progressive myoclonus epilepsy: long-term observations in seven patients. Epilepsy research. 1998;29(2):109–14. pmid:9477142.
- 41. Cardinali S, Canafoglia L, Bertoli S, Franceschetti S, Lanzi G, Tagliabue A, et al. A pilot study of a ketogenic diet in patients with Lafora body disease. Epilepsy research. 2006;69(2):129–34. pmid:16504479.
- 42.
Rusbridge C, Fitzmaurice SN, Lohi H, Young EJ, Minassian BA. Treatment of Lafora disease (inherited myoclonic epilepsy) in dogs In: Mayhew IG, Hahn CN, editors. European Society of Veterinary Neurology 18th Annual Symposium Glasgow 2004.
- 43.
Ahonen S, Grossman TP, Wang P, Turnbull J, Zhao X, Minassian BA. Antisense oligonucleotide therapy for the fatal epilepsy Lafora disease. 2nd Biennial International Lafora workshop in 23rd -24th June 2016; Sanford Consortium for Regenerative Medicine, La Jolla, California. 2016. p. 15.